Northwest BiotherapeuticsNWBO -0.58%17 Operating Margin % is -2,206.48% as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Northwest Biotherapeutics ranks worse than 87.3% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Northwest Biotherapeutics Operating Margin % Related Terms
Northwest Biotherapeutics Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NWBO vs PROK, AVIR, IMRX: Operating Margin % Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Northwest Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -2,206.48% mean?
Northwest Biotherapeutics (NWBO) has a Operating Margin % of -2,206.48% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Northwest Biotherapeutics and its competitors. According to the industry distribution chart, Northwest Biotherapeutics ranks #825 out of 945 companies in the Biotechnology industry, placing it in the top 87.3%.
Is Northwest Biotherapeutics' Operating Margin % too high?
Northwest Biotherapeutics' current Operating Margin % is -2,206.48%. Based on the distribution chart, Northwest Biotherapeutics ranks #825 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Operating Margin % compare to PROK and AVIR?
According to the Biotechnology industry distribution chart, Northwest Biotherapeutics ranks #825 out of 945 companies for Operating Margin %. This places Northwest Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Operating Margin % is -2,206.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Operating Margin % of -2,206.48%. The current Operating Margin % is -2,206.48%. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Operating Margin % is -2,206.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score
Get the complete analysis for NWBO
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NWBO has been successfully added to your 
